Sanofi

Upadacitinib (Rinvoq) demonstrated a favorable long-term benefit-risk profile through 76 weeks in adolescents with moderate to severe atopic dermatitis, achieving EASI-75 in 84-96% of patients across three phase III trials. Both 15 mg and 30 mg doses met primary endpoints, with acne and nausea as most common adverse events. Long-term outcomes were consistent with known AE profile, with no new signals observed. The analysis involved 542 adolescents, with data gathered from August 2018 to April 2022.

Dupixent (dupilumab) significantly reduced itch and urticaria activity scores in biologic-naive CSU patients on antihistamines, with 41% achieving well-controlled disease vs. 23% on placebo. Safety profile consistent with known dermatological indications.

Roche reported strong Q3 and nine-month results, with sales up 9% at constant exchange rates. Sanofi is in exclusive talks with CD&R to sell a controlling stake in its consumer healthcare business, Opella. The FDA approved Pfizer’s RSV vaccine, Abrysvo, for adults under 60. Novo Nordisk’s cardiovascular outcomes study on oral semaglutide met its primary endpoint, and AstraZeneca’s Wainzua received a positive CHMP recommendation for EU approval.

Agomab Therapeutics raises $89m in Series D funding, with Sanofi and Invus joining as new investors, to advance clinical trials of AGMB-129, an oral small molecule inhibitor for fibrostenosing Crohn’s disease, with interim results expected in early 2025.

The Anxiety Disorders and Depression Treatment Market was valued at USD 12.2 billion in 2023 and is projected to reach USD 16.65 billion by 2032, growing at a CAGR of 3.53%. This growth is driven by the rising prevalence of anxiety disorders and depression, advancements in pharmaceutical therapies, and increased awareness and destigmatization of mental health issues.

Newly described lymph node-like structures in liver tumors after immunotherapy may be crucial for treating hepatocellular carcinoma, potentially increasing the likelihood of curing the cancer, according to a study by Johns Hopkins researchers.

Dupixent phase 3 LIBERTY-CUPID Study C results show significant reduction in itch and urticaria activity scores, with higher disease control rates in chronic spontaneous urticaria patients on antihistamines, to be presented at ACAAI 2024.

Dupixent significantly reduced itch and hive activity in uncontrolled chronic spontaneous urticaria patients, with 41% achieving well-controlled disease status. Positive Phase 3 LIBERTY-CUPID Study C data support potential U.S. regulatory resubmission by year-end, aiming for Dupixent to be the first new targeted treatment for CSU in over 10 years.

Digital transformation in pharma is revolutionizing drug development, clinical trials, and patient interactions through AI, machine learning, and big data analytics, enhancing efficiency and personalization. About 55% of firms use digital technologies, optimizing processes and improving global healthcare. Key benefits include increased patient engagement, accelerated drug discovery, patient-driven research, gamification in health management, smart packaging solutions, crowdsourced clinical trials, ethical AI, integrated biometric monitoring, sustainability, and AI-powered decision support systems. Implementation steps involve establishing clear objectives, assessing current capabilities, formulating a strategic plan, investing in technologies, executing pilot projects, scaling successful initiatives, monitoring progress, and conducting regular evaluations. Real-life examples include Pfizer's AI-driven vaccine development, Novo Nordisk's AR in manufacturing, AstraZeneca's AI in cardiovascular trials, GSK's digital twin optimization, and Sanofi's digital quality assessment. Challenges such as legacy system integration, data security, cultural resistance, and fragmented data sources are addressed with phased modernization, robust cybersecurity, change management, and integrated data platforms.